1. Scrip

As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche

 
• By Jessica Merrill

The US FDA has granted priority review for Pfizer's talazoparib, which would be the fourth PARP inhibitor on the market, though only the second for breast cancer behind Lynparza. Pfizer has a long-term eye on a combination of talazoparib with its PD-L1 inhibitor Bavencio, Oncology CMO Rothenberg told Scrip at ASCO. 

Priority letters

With Pfizer Inc. nearing the market with its polyl (ADP-ribose) polymerase inhibitor talazoparib, the PARP class is starting to get crowded – and sponsors are looking to carve out niche sections of the market, as executives explained to Scrip at the recent American Society of Clinical Oncology annual meeting.

Pfizer is a step closer to getting the PARP inhibitor it gained with the acquisition of Medivation onto the market for breast cancer; Pfizer announced June 7 that the US FDA has accepted an NDA for talazoparib for the treatment of BRCA-mutated breast cancer with a priority review, and a

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.